There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Traditional antiviral vaccines have relied mostly on attenuated or chemically inactivated
live viruses. However, the potential problems related either to an incomplete inactivation
procedure or to the reversion of an attenuated vaccine strain result in growing concerns
for their use in human vaccination approaches.
Virus-like particles (VLPs) are based on the expression of virus capsid proteins,
which spontaneously assemble in particles structurally similar to native virus particles,
without containing viral genetic material. Thus, VLPs represent a non-replicating,
non-infectious particulate antigen delivery system able to present conformationally
structured viral proteins to the immune system. We have developed a candidate HIV-1
vaccine model based on HIV-1 Pr55gag VLPs (HIV-VLPs), produced in a baculovirus expression
system and presenting a gp120 molecule from a HIV-1 isolate of the clade A (HIV-VLPAs).
HIV-VLPAs induce in Balb/c mice systemic and mucosal neutralizing antibodies as well
as cytotoxic T lymphocytes, by intraperitoneal as well as intranasal administration.
HIV-VLPAs efficiently induce maturation and activation of MDDCs which show an enhanced
Th1- and Th2-specific cytokine production. In addition, HIV-VLP-loaded MDDCs are able
to induce a primary and secondary response in autologous human CD4+ T cells, in an
ex vivo immunization assay. The versatility of the presentation system, together with
the strong immunogenicity, make the VLP approach a highly valuable tool for vaccination
strategies.